Trial Profile

A Phase 2, Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Viagenpumatucel-L (HS-110) in Combination With Low Dose (Metronomic) Cyclophosphamide Versus Chemotherapy Alone in Patients With Non-Small Cell Lung Adenocarcinoma After Failure of Two or Three Previous Treatment Regimens for Advanced Disease

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Viagenpumatucel-L (Primary) ; Antineoplastics; Cyclophosphamide; Docetaxel; Erlotinib; Gemcitabine; Paclitaxel; Pemetrexed; Vinorelbine
Indications Adenocarcinoma; Non-small cell lung cancer
Focus Proof of concept; Therapeutic Use
Sponsors Scorpius Holdings

18 Apr 2018 According to a Heat Biologics media release, interim data readout is expected in Q4 2018 and final readout in Q2 2019.
07 Dec 2017 According to a Heat Biologics media release, data read-out is anticipated in the second half of 2018.
21 Apr 2017 Planned End Date changed from 1 Jun 2018 to 1 Sep 2018.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com